PMID- 30202411
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1658-3639 (Print)
IS  - 1658-3639 (Linking)
VI  - 12
IP  - 5
DP  - 2018 Sep-Oct
TI  - Cardiovascular outcomes and safety with antidiabetic drugs.
PG  - 70-83
AB  - Type 2 diabetes is a debilitating disease that impacts the life expectancy, 
      quality of life, and health of an individual. Cardiovascular disease (CVD) is a 
      common diabetes-associated complication and a principal cause for death in 
      diabetic patients. This review aims to investigate and summarize the effect of 
      Type 2 diabetes mellitus (T2DM) medications on CVD issues. A comprehensive 
      literature review mainly from level 1 evidence was performed. Thirty-seven 
      articles were extracted from Google Scholar, ScienceDirect, ProQuest, and PubMed 
      Database using a combination of keywords. The findings suggest that different 
      glucose-lowering agents have been tested for their efficacy and safety in T2DM 
      with CVD. Some of the recent trials such as the "United Kingdom Prospective 
      Diabetes Study," "Empagliflozin (EMPA) Cardiovascular (CV) Outcome Event Trial in 
      T2DM Patients-Removing Excess Glucose" (EMPA-REG OUTCOME), "Liraglutide Effect 
      and Action in Diabetes: Evaluation of CV Outcome Results," and "Trial to Evaluate 
      CV and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 
      Diabetes" (SUSTAIN6) have shed important light on this vital clinical concern, 
      thus demonstrating a convincing effect of liraglutide, semaglutide, and EMPA on 
      CVD outcomes, while metformin is thought to be the first-line optimal oral agent 
      to manage Type 2 diabetics. Some classes of drugs demonstrate CV protection, some 
      of them may be a result of a class effect, and some differences might be based on 
      the population enrolled individually. Most of the trials failed to show a 
      significant benefit with regard to mortality and morbidity in spite of intensive 
      glycemic control. This study, therefore, enabled us to develop a guide of 
      potential antidiabetic medication that can influence or promote CV health. Health 
      professionals in future should weigh the CV risk against possible advantages 
      while prescribing antidiabetic medications.
FAU - Aldossari, Khaled K
AU  - Aldossari KK
AD  - Department of Family and Community Medicine, College of Medicine, Prince Sattam 
      Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Saudi Arabia
TA  - Int J Health Sci (Qassim)
JT  - International journal of health sciences
JID - 101528042
PMC - PMC6124835
OTO - NOTNLM
OT  - Antidiabetic drugs
OT  - cardiovascular impact
OT  - cardiovascular risk
OT  - diabetes medications
OT  - type 2 diabetes
EDAT- 2018/09/12 06:00
MHDA- 2018/09/12 06:01
PMCR- 2018/09/01
CRDT- 2018/09/12 06:00
PHST- 2018/09/12 06:00 [entrez]
PHST- 2018/09/12 06:00 [pubmed]
PHST- 2018/09/12 06:01 [medline]
PHST- 2018/09/01 00:00 [pmc-release]
AID - IJHS-12-70 [pii]
PST - ppublish
SO  - Int J Health Sci (Qassim). 2018 Sep-Oct;12(5):70-83.